| Autor: |
Christopher J M, Williams, Jenny F, Seligmann, Faye, Elliott, Michael, Shires, Susan D, Richman, Sarah, Brown, Liping, Zhang, Shalini, Singh, Judith, Pugh, Xiao-Meng, Xu, Andrea, Muranyi, Christoph, Guetter, Auranuch, Lorsakul, Uday, Kurkure, Zuo, Zhao, Jim, Martin, Xingwei, Wang, Kien, Nguyen, Wen-Wei, Liu, Dongyao, Yan, Nicholas P, West, Jennifer H, Barrett, Michael, Barnes, Isaac, Bai, Matthew T, Seymour, Philip, Quirke, Kandavel, Shanmugam |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(12) |
| ISSN: |
1557-3265 |
| Popis: |
High tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC). However, ligand RNA assays have not been adopted into routine practice due to issues with analytic precision and practicality. We investigated whether AREG/EREG IHC could predict benefit from the anti-EGFR agent panitumumab.Artificial intelligence algorithms were developed to assess AREG/EREG IHC in 274 patients from the PICCOLO trial of irinotecan with or without panitumumab (Ir vs. IrPan) inHigh ligand expression was associated with significant PFS benefit from IrPan compared with Ir [8.0 vs. 3.2 months; HR, 0.54; 95% confidence interval (CI), 0.37-0.79;AREG/EREG IHC identified patients who benefitted from the addition of panitumumab to irinotecan chemotherapy. IHC is a practicable assay that may be of use in routine practice. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
